Archer Daniels Midland: DOJ and SEC investigations into Nutrition segment accounting irregularities 2025

SEC Finalizes $40 Million Penalty for Accounting Fraud

The Securities and Exchange Commission (SEC) finalized a $40 million civil penalty against Archer-Daniels-Midland (ADM) on January 28, 2026, resolving a two-year investigation into accounting irregularities within its Nutrition segment. The settlement addresses charges that the agribusiness giant materially inflated the operating profit of its Nutrition division to meet executive bonus goals and investor expectations. Simultaneously, the Department of Justice (DOJ) closed its parallel criminal investigation without bringing charges against the corporation, though individual executives remain in legal jeopardy. This resolution follows a period of intense scrutiny that began in January 2024, when ADM placed then-CFO Vikram Luthar on administrative leave and withdrew its forward-looking financial guidance. The SEC’s order finds that ADM violated antifraud, reporting, and internal control provisions of federal securities laws. The company agreed to the penalty and a cease-and-desist order without admitting or denying the findings.

The “Intersegment” Inflation Scheme

The SEC investigation focused on specific accounting maneuvers used between 2021 and 2022. Investigators found that ADM executives directed “adjustments” to intersegment transactions, sales of goods between ADM’s own divisions, to artificially boost the profitability of the Nutrition segment. The Nutrition unit, marketed to investors as a high-growth engine, struggled to meet its projected 15% to 20% annual operating profit growth. To mask these shortfalls, executives allegedly executed retroactive rebates and price changes on ingredients sold by the Ag Services & Oilseeds and Carbohydrate Solutions segments to the Nutrition segment. These adjustments were not based on market forces were instead designed to transfer profit into the Nutrition book. The SEC complaint states these changes were “not customarily available to ADM’s third-party customers” and served primarily to align reported results with internal compensation metrics.

Executive Penalties and Ongoing Litigation

While ADM as a corporate entity settled, the legal for individual executives varies. The SEC filed a litigated action against former CFO Vikram Luthar, charging him with violating antifraud provisions and aiding and abetting the company’s violations. Luthar, who resigned in April 2024, contests the charges. His defense team asserts the transactions were transparent and approved in good faith. Two other former executives settled with the SEC. Vince Macciocchi, the former President of the Nutrition business, and Ray Young, a former CFO and Vice Chairman, agreed to civil penalties and disgorgement.

Financial Restatements and Market Reaction

The accounting improper practices forced ADM to restate its financial reports for fiscal year 2023 and the two quarters of 2024. The corrections resulted in a reduction of reported Nutrition segment operating profit by approximately $228 million over the affected period. When the scandal broke in January 2024, ADM’s stock price plummeted 24% in a single day, erasing $8. 8 billion in market value. The DOJ’s decision to decline prosecution removes the threat of a corporate criminal conviction, a serious risk for a company heavily involved in government contracts and global trade. The declination aligns with recent DOJ policies that favor companies who self-report or cooperate extensively, though ADM’s cooperation credit was debated given the initial delays in disclosure.

Remedial Measures and Internal Controls

In response to the investigation, ADM implemented new internal accounting controls specifically governing intersegment sales. The company also revised its compensation policies. In March 2025, the board exercised “negative discretion” to cut CEO Juan Luciano’s cash bonus by more than 50%, reducing his total compensation to $21. 6 million from $24. 4 million the prior year. The company also introduced a clawback policy allowing the recovery of stock awards from executives engaged in misconduct, regardless of whether they are terminated.

“The adjustments created the illusion that Nutrition was reaching the 15% to 20% per year operating profit growth that Luthar had, alongside other ADM executives, projected to investors.” , SEC Complaint, Jan 27, 2026.

Investigation Timeline and Key Events

* June 2023: SEC problem voluntary document request regarding intersegment sales. * January 2024: ADM places CFO Vikram Luthar on leave; stock drops 24%. * April 2024: Luthar resigns; internal investigation confirms material weakness in controls. * November 2024: ADM identifies further accounting errors, delays earnings call. * March 2025: Board cuts CEO bonus; new clawback policies enacted. * January 2026: SEC settles with ADM ($40M), Macciocchi, and Young; sues Luthar. DOJ closes inquiry. The $40 million penalty represents a significant regulatory rebuke remains a fraction of ADM’s annual revenue. The focus shifts to the courtroom, where the SEC’s case against Vikram Luthar likely expose further details about the internal decision-making processes that led to the accounting failures. The company maintains that the accounting adjustments had no impact on its consolidated balance sheet, earnings, or cash flows, as the money was shifted between internal buckets. Yet, the misrepresentation of the Nutrition segment’s health misled investors about the success of ADM’s strategic pivot toward high-margin specialty ingredients.

DOJ Declination: The “No Further Action” Verdict

On January 27, 2026, the U. S. Department of Justice (DOJ) formally closed its criminal investigation into Archer-Daniels-Midland (ADM) regarding accounting irregularities in its Nutrition segment. In a decisive outcome for the agribusiness giant, federal prosecutors issued a “no further action” notice, clearing the corporation of criminal liability after a sprawling two-year probe. This declination stands in clear contrast to the parallel civil enforcement by the Securities and Exchange Commission (SEC), which levied a $40 million penalty just one day later.

The DOJ’s decision to walk away without filing charges marks a significant victory for ADM’s legal defense strategy, which hinged on aggressive cooperation and voluntary remediation. While the investigation confirmed that the company had artificially inflated the operating profits of its Nutrition division by shifting funds from other business units, prosecutors determined that ADM’s internal corrective actions were sufficient to avoid a corporate criminal plea or deferred prosecution agreement (DPA).

Corporate Immunity Secured

The closure of the DOJ file ends the threat of a criminal conviction that could have jeopardized ADM’s federal contracts and agricultural licenses. Unlike the SEC settlement, which required a monetary penalty, the DOJ resolution involved no fines, no probation, and no independent compliance monitor. The “no further action” letter indicates that the U. S. Attorney’s Office for the Southern District of New York found the company’s self-reporting and subsequent cleanup efforts met the threshold for leniency under current corporate enforcement policies.

ADM CEO Juan Luciano, who faced intense scrutiny during the probe, characterized the closure as a pivotal moment for the company. “We are pleased to put these matters behind the Company,” Luciano stated in a January 27 release. “These past couple of years have underscored what’s core to ADM , incorporating learnings to further strengthen our business.”

The “Cooperation” Defense

Federal prosecutors ADM’s proactive measures as the primary justification for declining prosecution. Following the initial exposure of the accounting anomalies in January 2024, the company’s Audit Committee commissioned an independent internal investigation and voluntarily disclosed the findings to government agencies. Key remedial steps included:

• Financial Restatements: ADM corrected six years of financial data, erasing approximately $228 million in operating profit previously attributed to the Nutrition segment.
• Executive Terminations: The company accepted the resignation of CFO Vikram Luthar and removed other executives implicated in the intersegment transfer scheme.
• Internal Controls: Implementation of rigorous new for recording “intersegment” sales to prevent future profit shifting.

By serving up the responsible individuals and correcting the books before the DOJ could file an indictment, ADM successfully shifted the legal load from the corporation to its former officers.

Civil Liability vs. Criminal Liberty

While the corporation avoided criminal charges, the for individual executives remains severe, albeit confined to civil courts. The DOJ’s exit leaves the SEC as the sole federal enforcer pursuing the architects of the scheme. Former CFO Vikram Luthar, who was placed on administrative leave in January 2024 and resigned later that year, faces a litigated civil fraud action by the SEC. Luthar has refused to settle, with his defense counsel Junaid Zubairi calling the allegations “meritless” and arguing that the transactions were “transparent” business practices.

Conversely, two other executives, former Nutrition President Vince Macciocchi and former CFO Ray Young, opted to settle with the SEC, agreeing to civil penalties and disgorgement without admitting wrongdoing. The between the corporate outcome (total clearance) and the individual outcomes (civil prosecution) highlights the DOJ’s focus on widespread remediation over corporate punishment in this instance.

Table: Federal Investigation Outcomes (Jan 2026)

“The DOJ has closed its investigation of ADM with no further action… These outcomes end the investigations of ADM by the SEC and DOJ.” , ADM Official Statement, January 27, 2026

The “Nutrition” Scheme Mechanics

The investigation centered on the “Nutrition” segment, a division ADM had touted to investors as a high-growth engine for the future. To meet aggressive profit of 15% to 20% annual growth, executives allegedly utilized “intersegment” transactions, selling goods between ADM divisions, at non-market rates. Specifically, the Ag Services and Carbohydrate Solutions units sold ingredients to the Nutrition unit at artificially low prices, or provided retroactive “rebates.”

These internal transfers acted as a subsidy, inflating Nutrition’s operating profit by millions of dollars while depressing the profits of the donor segments. Because executive compensation was tied specifically to the growth of the Nutrition unit, the scheme directly enriched leadership at the expense of accurate financial reporting. The DOJ’s decision not to prosecute suggests they viewed this as a manipulation of internal metrics rather than a criminal theft from shareholders, provided the company corrected the record.

The Sole Dissenter: Luthar Rejects SEC Settlement

While Archer-Daniels-Midland and other executives moved to settle charges in early 2026, former Chief Financial Officer Vikram Luthar broke ranks, refusing the Securities and Exchange Commission’s settlement offer. This decision, following a contentious year of negotiations in 2025, sets the stage for a high- legal battle. Luthar, who served as CFO of the Nutrition segment before his promotion to the top finance role in 2022, stands accused of orchestrating the accounting irregularities that forced the company to restate six years of financial data.

Luthar’s refusal to settle from his defense team’s assertion that his actions were consistent with long-standing company practices and approved by internal controls. His attorney, Junaid Zubairi, publicly stated that ADM’s own internal investigation, disclosed in the March 25, 2025, proxy statement, did not find Luthar to have engaged in “improper conduct.” This defense contradicts the SEC’s position that Luthar directed “adjustments” to intersegment transactions specifically to manufacture growth metrics.

The “Growth Engine” Allegations

The core of the litigation focuses on Luthar’s management of the Nutrition segment between 2021 and 2022. The SEC alleges that Luthar faced immense pressure to deliver on the “15% to 20%” annual operating profit growth promised to investors. When the segment fell short, investigators claim Luthar directed the transfer of profits from other divisions, specifically Ag Services and Oilseeds, into Nutrition through retroactive rebates and “risk-sharing” agreements.

These adjustments, which the SEC characterizes as having no economic substance, allowed the Nutrition unit to report a 20% profit increase in 2021. Following the internal probe in March 2024, ADM revised this figure down to 13%. The cumulative impact of these accounting maneuvers required ADM to slash $228 million from the Nutrition segment’s reported operating profit for the period spanning 2018 to 2023.

Resignation and Compensation Clawbacks

Luthar’s departure from ADM was formalized in a “transition agreement” signed in April 2024, with his resignation September 30, 2024. Under the terms of this agreement, Luthar continued to receive his annual base salary of $770, 840 and his 2023 cash performance bonus of $743, 419. yet, the agreement explicitly left him to future clawbacks depending on the outcome of regulatory probes.

The SEC is seeking not only civil penalties also the reimbursement of these incentive-based payments under Section 304 of the Sarbanes-Oxley Act. The agency that Luthar personally benefited from the fraud, citing his sale of approximately $1. 8 million in ADM stock during the period when share prices were allegedly inflated by the misleading Nutrition results.

“The transactions in question were transparent and were considered, approved, and implemented in good faith at the company. Mr. Luthar was not interested in a settlement with the SEC.” , Statement by Junaid Zubairi, Counsel for Vikram Luthar (Late 2025)

The Defense Strategy

Luthar’s legal strategy relies heavily on the “good faith” argument and the absence of criminal intent findings in ADM’s internal review. His team points to the fact that the adjustments, while later deemed improper, were recorded in the company’s books and approved by other executives, including those who have since settled. By refusing the settlement, Luthar forces the SEC to prove in federal court that he knowingly deceived investors, a higher load of proof than required for a negotiated administrative settlement.

The outcome of this litigation determine whether the accounting failures were the result of a single executive’s manipulation or a widespread corporate culture that prioritized meeting aggressive over financial accuracy.

Forensic Mechanics: Retroactive Rebates and Price Adjustments

The accounting irregularities at Archer-Daniels-Midland (ADM) were not the result of complex derivatives or offshore shell companies, rather a crude manipulation of internal transfer pricing designed to manufacture growth in the Nutrition segment. The mechanics of the fraud relied on “retroactive rebates” and “price adjustments”, accounting levers pulled after the close of financial periods to shift operating profit from the Ag Services and Carbohydrate Solutions segments into Nutrition.

The “Risk Sharing” Euphemism

Federal investigators found that former CFO Vikram Luthar and other executives utilized a specific internal justification to alter financial records: “risk sharing.” This term served as a euphemism for rewriting history. When the Nutrition segment failed to meet its projected 15% to 20% annual operating profit growth , metrics directly tied to executive compensation, management directed the retroactive alteration of intersegment transfer prices. These adjustments were not based on market or contractual obligations. Instead, they were unilateral transfers. For example, if the Carbohydrate Solutions segment sold ethanol or corn syrup to the Nutrition segment earlier in the year, the price of those completed transactions would be lowered retroactively. This action reduced the cost of goods sold (COGS) for Nutrition, instantly inflating its operating profit, while simultaneously reducing the profit of the Carbohydrate segment.

Anatomy of the Transaction Loop

The forensic breakdown of these transactions reveals a consistent pattern used primarily during fiscal years 2021 and 2022.

Step 1: The Shortfall Identification
Near the end of a reporting period, finance executives identified that the Nutrition segment was tracking its double-digit growth.

Step 2: The “Piggybank” Extraction
Executives treated the massive Ag Services and Carbohydrate Solutions segments, which generate billions in stable low-growth profit, as a “piggybank.” They identified specific intersegment transactions that could be adjusted.

Step 3: The Retroactive Adjustment
Finance teams processed “rebates” for goods already sold and consumed. These rebates had no commercial substance; they were not offered to third-party customers and existed solely to move internal capital. The SEC complaint noted that these adjustments allowed Nutrition to “pick better historical prices” for sales that were already finalized.

Step 4: The Zero-Sum Consolidation
Because these were internal transfers, they netted to zero on ADM’s consolidated financial statements. The “Corporate” line item in financial reports, frequently a catch-all for unallocated expenses and eliminations, absorbed the accounting friction. This allowed ADM to report accurate total earnings to the IRS and shareholders while presenting a falsified growth narrative for its strategic Nutrition unit.

Quantifying the

The impact of these mechanics was material. The adjustments artificially inflated the Nutrition segment’s operating profit by as much as 9. 2% in certain periods. In March 2024, ADM was forced to restate its financials, wiping out $228 million in segment operating profit that had been fabricated between 2018 and 2023.

The “One-Sided” Nature of Transfers

The Department of Justice and SEC investigations emphasized that these transfers were “one-sided.” In a legitimate arm’s-length transaction, a price adjustment might reflect a volume discount or a quality problem. In ADM’s case, the adjustments were purely financial instruments used to fill a budget gap. The Carbohydrate and Ag Services units received no tangible benefit for surrendering their profits; they simply absorbed the loss to prop up the Nutrition narrative. This practice violated the core accounting principle that intersegment sales must be recorded at amounts “approximating market.” By systematically underpricing goods sold to Nutrition—or rebating them retroactively—ADM subsidized the segment’s operations, concealing its actual performance struggles from investors who were paying a premium for the stock based on its growth chance.

The Settlement: Admissions and Penalties

On January 27, 2026, the Securities and Exchange Commission (SEC) announced settled charges against two former Archer-Daniels-Midland (ADM) executives, Vincent Macciocchi and Ray G. Young, ending their involvement in the accounting scandal that erased billions in market value. Unlike former CFO Vikram Luthar, who chose to contest the allegations in federal court, Macciocchi and Young accepted civil penalties and disgorgement orders to resolve charges related to the inflation of the Nutrition segment’s operating profit.

The settlements mark the individual accountability for the “intersegment” transfer pricing scheme. The SEC’s orders confirm that the manipulation was not a corporate oversight involved specific actions by senior leadership to bypass internal controls and manufacture growth metrics demanded by Wall Street.

Vincent Macciocchi: The Architect of Adjustment

Vincent Macciocchi, the former Senior Vice President and Head of Nutrition, faced the brunt of the conduct-based allegations. As the executive directly responsible for the unit’s performance, Macciocchi was identified by the SEC as a central figure in structuring the “adjustments” that artificially boosted profitability. The investigation found that when the Nutrition segment was in danger of missing its 15% to 20% annual operating profit growth , a key metric for executive bonuses, Macciocchi coordinated with finance personnel to transfer funds from other ADM divisions.

Under the terms of the settlement, Macciocchi agreed to a three-year officer and director bar, legally preventing him from serving in senior governance roles at any public company until 2029. This sanction his immediate career prospects in corporate leadership. Finanically, Macciocchi must pay a total of $529, 343. This sum includes $125, 000 in civil penalties and $404, 343 in disgorgement and prejudgment interest, representing the performance bonuses he received based on the fraudulent data.

“Macciocchi and Luthar led efforts to identify and structure adjustments for fiscal years 2021 and 2022… targeted to specific dollar amounts to hit Nutrition’s operating profit goals or mask a shortfall.” , SEC Settlement Order, Jan 27, 2026

Ray Young: Negligence at the Top

Ray G. Young, ADM’s former CFO and Vice Chairman who retired in 2022, faced charges rooted in negligence rather than the active orchestration attributed to Macciocchi and Luthar. The SEC found that Young, while serving as CFO, “negligently approved” improper adjustments for fiscal years 2019 and 2021. His failure to scrutinize the retroactive rebates and transfer pricing anomalies allowed the scheme to during his tenure.

even with the finding of negligence rather than intentional fraud, Young’s financial sanction exceeded Macciocchi’s due to the size of the compensation he received during the affected periods. Young agreed to pay a total of $650, 610. This figure comprises a $75, 000 civil penalty and $575, 610 in disgorgement and interest. The in disgorgement highlights that while Young’s culpability was legally lower (negligence vs. scienter-based fraud), his financial benefit from the inflated metrics was significantly higher.

Sanctions Breakdown

The following table details the specific financial penalties and professional restrictions imposed on the two executives.

The Economics of Disgorgement

The “disgorgement” component of these sanctions is serious to understanding the motive behind the accounting irregularities. The SEC uses disgorgement to claw back “ill-gotten gains.” In this case, the amounts correspond to the specific portion of executive bonuses that were triggered by the Nutrition segment hitting its inflated. By forcing the return of these funds, the SEC established that the executives personally profited from the misleading financial reports.

The absence of a professional bar for Ray Young suggests the regulators distinguished between his oversight failures and the active manipulation alleged against Macciocchi and Luthar. Young’s settlement allows him to retain his ability to serve on boards, a crucial distinction for a retired executive of his stature, whereas Macciocchi’s three-year ban serves as a punitive “time-out” from the corporate world.

The Billion-Dollar pledge

Between 2020 and 2023, Archer-Daniels-Midland (ADM) executives aggressively marketed the Nutrition segment as the engine of the company’s future, distinguishing it from the volatile, low-margin commodity trading business that defined its history. Central to this narrative was a specific, repeated financial target: the Nutrition unit would deliver annual operating profit growth of 15% to 20%. This metric was not an internal goal a public pledge to Wall Street, used to justify a higher stock valuation and validate the company’s strategic pivot.

CEO Juan Luciano and then-CFO Vikram Luthar frequently touted these figures in earnings calls and investor presentations. During a May 2022 conference, Luciano explicitly stated that the Nutrition business was on a “clear runway to growth of 15% to 20% over the 5 to 10 years.” He further projected that the segment would generate “north of $800 million in operating profit” in 2022 and reach $1 billion by 2023. These projections served as the of ADM’s investment thesis, promising investors that the company had successfully diversified into high-margin ingredients like probiotics, alternative proteins, and natural flavors.

The Valuation Gap

The pressure to hit these was immense. ADM’s traditional agricultural services business commanded a lower price-to-earnings (P/E) multiple, reflecting the cyclical nature of grain markets. By contrast, the Nutrition segment was positioned to trade at valuations comparable to specialized ingredient companies like Kerry Group or DSM, which frequently commanded multiples double that of grain traders. Consequently, the “20% growth” narrative was directly linked to billions of dollars in market capitalization.

This strategic importance was codified in executive compensation. The ADM board linked of senior executives’ long-term incentive pay specifically to the Nutrition segment’s performance. For the fiscal years 2020 through 2022, hitting the double-digit growth was a prerequisite for maximum bonus payouts, creating a direct financial motive to ensure the reported numbers matched the ambitious guidance.

Fabricating Growth: The 2021-2022 gap

As market conditions tightened in 2021 and 2022, the Nutrition segment began to falter organically. Rising input costs and operational challenges meant the unit was on track to miss its 15-20% growth significantly. According to the SEC complaint filed in January 2026, it was during this period that Vikram Luthar intervened to the gap between reality and the “growth mirage” sold to investors.

In 2021, Luthar represented to investors that the Nutrition segment had achieved 20% operating profit growth. In reality, this figure was manufactured through inter-segment “adjustments”, essentially transferring profits from the Ag Services & Oilseeds division to Nutrition. Without these transfers, the segment’s growth would have been materially lower, exposing the stagnation of the company’s prized growth engine. Similarly, in 2022, when the segment was struggling to show even modest gains, Luthar directed subordinates to find approximately $20 million al adjustments to ensure the unit appeared to meet its revised forecasts.

The Restatement Reality

The extent of the fabrication was revealed when ADM was forced to restate its financial results. The company admitted that it had overstated the Nutrition segment’s operating profit by as much as 9. 2% in certain years. The cumulative effect was a reduction of $228 million in Nutrition operating profit between 2018 and 2023. The restated figures painted a clear different picture of the business’s trajectory:

The 2023 collapse was particularly damning. Far from the $1 billion operating profit promised by Luciano, the segment delivered only $427 million, a 36% year-over-year decline. This massive miss confirmed that the previous years’ “steady growth” had been artificially smoothed by accounting manipulations, masking the segment’s true volatility and operational weaknesses.

Investor

The that the 20% growth target was a fabrication shattered investor confidence. When the accounting problem surfaced, ADM’s stock plummeted, wiping out over $8 billion in market value in a single day. The “growth mirage” had successfully buoyed the stock price for two years, the correction was swift and severe. The SEC’s January 2026 settlement confirmed that investors had been misled about the fundamental health of the business, noting that the “adjustments” concealed the fact that Nutrition was not the self-sustaining growth engine it was portrayed to be.

By 2025, the narrative had shifted entirely. Instead of touting aggressive double-digit growth, ADM’s leadership was forced to focus on “stabilizing” the Nutrition segment and “regaining credibility.” The $1 billion profit target, once presented as a near-term certainty, was indefinitely shelved, a casualty of the forensic audit that exposed the artificial supports holding it up.

The Engine of Fraud: Nutrition Operating Profit

The accounting irregularities at Archer-Daniels-Midland were not abstract financial manipulations; they were directly tethered to the personal enrichment of the company’s top executives through specific, quantified compensation metrics. Between 2020 and 2022, ADM’s executive compensation committee explicitly linked the vesting of Performance Share Units (PSUs) to the growth of the Nutrition segment’s operating profit. This decision monetized the “15% to 20%” growth narrative, creating a direct financial incentive for executives to manufacture results when market realities failed to deliver them.

For the 2020 PSU pattern, which covered the performance period from 2020 to 2022, the compensation structure was heavily weighted toward two metrics: Adjusted Return on Invested Capital (ROIC) and Average Nutrition Operating Profit Growth. The target for the latter was aggressive, requiring double-digit expansion in a volatile market. According to ADM’s 2023 proxy statement, the Nutrition segment reportedly achieved an average operating profit growth of 21. 4% over this period. This figure, understood to be inflated by fraudulent intersegment transfers, triggered a maximum payout factor of 200% for that specific metric. Consequently, executives were awarded double the target number of shares, a windfall worth millions, based entirely on financial that had been artificially met.

Targeted Adjustments to Clear Bonus Thresholds

The Securities and Exchange Commission’s investigation revealed that the accounting adjustments were not random errors precision instruments used to the gap between actual performance and bonus thresholds. The SEC complaint against former CFO Vikram Luthar alleges that “adjustments were targeted to specific dollar amounts” required to hit the operating profit goals. When the Nutrition segment fell short of the 15-20% growth in 2021 and 2022, executives allegedly directed the transfer of operating profit from the Ag Services and Oilseeds segments to Nutrition through retroactive “rebates” and “risk-sharing” fees.

These transfers were timed to align with reporting periods for executive compensation. For instance, the SEC noted that Luthar personally pocketed a $130, 000 cash bonus that was partially contingent on the Nutrition segment hitting its profit goals. The mechanics of the fraud, shifting expenses out of Nutrition and revenue into it, ensured that the segment appeared to be a high-growth engine, so unlocking the maximum tier of variable compensation for leadership.

Disgorgement and the SOX 304 Clawback

The resolution of the SEC charges in January 2026 triggered significant financial penalties for the executives involved, utilizing the “clawback” provisions of the Sarbanes-Oxley Act (SOX). While ADM paid a corporate penalty of $40 million, the individual settlements required the return of ill-gotten gains.

Ray Young, who served as CFO during the earlier phase of the irregularities, agreed to disgorge over $575, 000, representing the portion of his compensation deemed to be derived from the inflated metrics. Vincent Macciocchi, the head of the Nutrition unit, forfeited over $400, 000. These figures represent the specific “delta” between what the executives were paid based on the fraudulent numbers and what they would have earned had the books been accurate.

Luthar’s Compensation Battle

Unlike his colleagues, Vikram Luthar has refused to settle, leading to a legal battle where his compensation remains a central focus. The SEC is pursuing a clawback under Section 304 of the Sarbanes-Oxley Act, seeking to force Luthar to reimburse ADM for bonuses and stock sales. The are high; to the $130, 000 cash bonus in the complaint, Luthar’s 2021 PSUs, which were initially deemed “earned at 100% of target” in March 2024, were withheld by the board following the launch of the internal investigation. The SEC’s litigation aims to permanently bar Luthar from serving as an officer or director of a public company and to recoup the full value of the incentive pay he received during the period of the alleged fraud.

The “Piggybank”: Ag Services as the Funding Source

The forensic heart of the Archer-Daniels-Midland (ADM) accounting scandal lies in the exploitation of its largest and most volatile division: Ag Services and Oilseeds (AS&O). While the Nutrition segment was publicly touted as the high-margin future of the company, it was, in reality, being artificially propped up by the massive balance sheet of the legacy grain trading business. Investigations by the DOJ and SEC revealed that AS&O did not sell raw materials to Nutrition; it functioned as a discretionary “piggybank,” absorbing costs and transferring profits to ensure the Nutrition segment met its aggressive 15-20% annual operating profit growth.

This subsidization was executed through the manipulation of intersegment transfer pricing, the internal rates at which goods are sold between company divisions. Under standard accounting principles and ADM’s own stated policies, these transfers must occur at “market rates” to accurately reflect the standalone performance of each unit. yet, from 2019 through 2023, ADM executives, including former CFO Vikram Luthar, directed the application of retroactive rebates and off-market pricing adjustments that systematically siphoned operating profit from AS&O and deposited it into Nutrition.

The “White Flake” method

The specific mechanics of this fraud were frequently crude rather than complex. A definitive example in the SEC’s January 2026 complaint involves “white flake,” a soy-based protein substrate used in various food ingredients. In 2020, the Nutrition segment contracted to purchase white flake from the Oilseeds division. The internal transfer price was initially set at market rates. yet, as global soybean prices surged later that year, the Nutrition segment, which had already locked in sales contracts with third-party customers based on lower input costs, faced the prospect of a significant operating loss on those deals.

Instead of allowing the Nutrition segment to report this market-driven loss, executives intervened. The SEC investigation found that Luthar and other senior leaders directed the Oilseeds unit to retroactively lower the transfer price of the white flake sold to Nutrition. This adjustment had no basis in market reality; it was a unilateral accounting entry designed solely to neutralize the commodity price spike for Nutrition. The result was a “one-sided transfer of operating profit” where the Oilseeds division absorbed the input cost inflation, shielding Nutrition’s margins from the volatility that should have naturally impacted its bottom line.

Quantifying the Subsidy

The of these transfers was calibrated to hit specific earnings-per-share (EPS) and segment operating profit. In 2019 alone, a single set of retroactive rebates shifted approximately $4. 7 million in operating profit to Nutrition. While this figure appears minor against ADM’s consolidated billions, it was material to the Nutrition segment’s reported growth trajectory, allowing it to the gap between actual performance and the “double-digit growth” promised to Wall Street.

The cumulative effect of these manipulations was a material of segment reporting. By suppressing the profitability of AS&O, a segment generating billions in operating profit where a few million dollars in variance could easily be buried in the noise of global grain volatility, ADM inflated the profitability of Nutrition by as much as 9. 2% in certain reporting periods. This created a false narrative of stability and execution in the Nutrition business, which was serious for ADM’s valuation multiple expansion.

The “Market Price” Fiction

For years, ADM’s financial filings contained a standard disclosure asserting that intersegment sales were recorded at amounts “approximating market.” The SEC’s January 2026 order exposed this statement as materially false. The adjustments directed by Luthar and executed by segment leadership were not available to third-party customers and divorced from market.

The internal rationale for these transfers relied on the opacity of the Ag Services behemoth. Because AS&O’s profits fluctuate wildly based on harvest yields, river logistics, and geopolitical trade flows, “missing” profit in that segment was far less likely to trigger analyst scrutiny than a growth stall in the high-multiple Nutrition unit. Executives treated the legacy business as a slush fund, withdrawing earnings as needed to smooth the volatility of the newer, more sensitive segment.

Restatement and Reallocation

The unraveling of this scheme necessitated the massive financial restatements filed in November 2024. ADM was forced to correct six years of financial data, reversing the illicit transfers. The restatement process involved:

Correction method: “The Company identified and corrected certain intersegment sales… that were not recorded at market rates. 2023 Ag Services & Oilseeds, Carbohydrate Solutions, and Nutrition segment operating profits have been restated to reflect corrections with no change to total Segment Operating Profit.”

The mathematical consequence of these corrections was a retroactive increase in Ag Services’ historical operating profit and a corresponding decrease in Nutrition’s. This restatement shattered the illusion of the Nutrition segment’s standalone viability, revealing that its “steady” growth had been partly financed by the grain silos and crushing plants of the legacy business. The adjustments confirmed that without the AS&O subsidy, the Nutrition segment had repeatedly failed to meet the 15-20% growth that triggered executive stock vestings.

Financial Restatements: Correcting 2018-2023 Reporting Errors

On November 18, 2024, Archer-Daniels-Midland (ADM) filed an amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, formally restating six years of financial data. This filing marked the culmination of an internal investigation that exposed a systematic manipulation of segment-level reporting designed to artificially the profitability of the Nutrition division. The restatement covered the period from January 1, 2018, through December 31, 2023, and corrected material misstatements in the company’s historical segment operating profits.

The $228 Million Adjustment

The core of the restatement involved the reversal of improper intersegment transactions that had shifted profits from ADM’s legacy agricultural businesses to its newer Nutrition segment. Over the six-year period, ADM reduced the reported operating profit of the Nutrition segment by a cumulative $228 million. These adjustments confirmed that the division had significantly underperformed the growth touted by executives to investors.

The restatement revealed that the Nutrition segment’s profitability was inflated through “retroactive rebates” and “price adjustments” on ingredients transferred from the Ag Services & Oilseeds and Carbohydrate Solutions segments. These internal transfers were not recorded at market rates, subsidizing the Nutrition division’s margins at the expense of the other units.

Year-by-Year Impact on Nutrition Operating Profit

The corrected figures dismantled the narrative of explosive growth in the Nutrition segment. The restatement significantly altered the profitability profile of the division during key years where executive compensation was tied to performance metrics.

The adjustments for 2022 were particularly damaging to the company’s prior claims. Originally, ADM reported that the Nutrition segment earned $736 million in operating profit for that year. The restatement slashed this figure to $668 million, a reduction of nearly 10%. Similarly, the 2021 growth rate, which had been celebrated as a 20% year-over-year increase, was revised down to approximately 13%.

Zero-Sum Consolidated Impact

ADM emphasized throughout the process that the restatements had no impact on consolidated earnings, cash flows, or the balance sheet. Because the fraud involved moving money from one internal pocket to another, the total company-wide profit remained unchanged. The $228 million removed from the Nutrition segment was reallocated back to the Ag Services & Oilseeds and Carbohydrate Solutions segments.

This “zero-sum” defense, yet, obscured the strategic damage. By inflating the Nutrition segment, ADM had presented a false picture of diversification to Wall Street. The company traded at a higher valuation multiple because investors believed the high-margin Nutrition business was growing rapidly. The restatement confirmed that ADM was still far more reliant on its lower-margin commodity trading and processing businesses than previously disclosed.

Material Weakness in Internal Controls

In conjunction with the financial restatements, ADM management identified a material weakness in internal control over financial reporting. The company admitted that it absence adequate controls to monitor and validate the pricing of intersegment sales. Specifically, the accounting team did not have sufficient oversight to ensure that transfers between divisions were recorded at amounts approximating market value, as required by Generally Accepted Accounting Principles (GAAP).

The material weakness disclosure in the amended 10-K/A indicated that the failure was not a clerical error a breakdown in the governance structure that allowed executives to override standard accounting. The company committed to a remediation plan, which included enhancing documentation requirements for intersegment pricing and increasing the frequency of internal audits on segment-level reporting.

“The adjustments resulted in transactions inconsistent with ADM’s representation that intersegment transactions were recorded at amounts ‘approximating market’.” , SEC Cease-and-Desist Order, January 2026

Timeline of Filings

The route to the final restatement was prolonged and marked by delays that rattled investor confidence:

• January 21, 2024: ADM announces the internal investigation and delays its Q4 2023 earnings release.
• March 12, 2024: ADM files its original 2023 Form 10-K, including preliminary corrections for intersegment sales.
• November 18, 2024: ADM files the definitive amended 2023 Form 10-K/A and amended 10-Qs for the and second quarters of 2024. These filings finalized the restated numbers for the 2018-2023 period.

The November 2024 filing closed the books on the accounting mechanics of the scandal, establishing the official financial record that would later serve as the basis for the SEC’s civil penalty and the DOJ’s investigation closure in early 2026.

Internal Control Failures: Material Weaknesses in Financial Reporting

The accounting irregularities that forced Archer-Daniels-Midland (ADM) to pay a $40 million SEC penalty in January 2026 were not the result of rogue actors; they were symptoms of a widespread collapse in the company’s internal control architecture. For years, the method designed to validate financial data failed to detect that the Nutrition segment’s growth was being artificially manufactured through manipulated intersegment transfer pricing.

The Official Declaration of Failure

In its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed in March 2024, ADM formally disclosed a “material weakness” in its internal control over financial reporting. This disclosure marked a serious turning point, stripping away the company’s previous assertions of financial integrity. The specific weakness identified was a failure in the accounting practices and procedures for intersegment sales, transactions between ADM’s own divisions. These controls were insufficient to ensure that goods transferred from the Ag Services and Oilseeds or Carbohydrate Solutions segments to the Nutrition segment were recorded at amounts approximating market value. Instead, the absence of rigorous oversight allowed executives to dictate pricing adjustments retroactively, treating internal accounting as a discretionary lever to meet external profit.

Ernst & Young’s Adverse Opinion

The severity of the control failure compelled ADM’s independent auditor, Ernst & Young LLP (EY), to problem an adverse opinion on the company’s internal controls. After years of issuing unqualified (“clean”) opinions, EY concluded in the 2023 filing that ADM had “not maintained internal control over financial reporting.” This adverse opinion highlighted a fundamental breakdown in the “checks and balances” expected of a Fortune 50 corporation. The auditors noted that the deficiency created a reasonable possibility that a material misstatement of the company’s annual or interim financial statements would not be prevented or detected on a timely basis. The failure was not a minor technicality; it was a gaping hole in the financial validation process that allowed hundreds of millions of dollars in profit to be misallocated over a five-year period (2019, 2023).

The method of Control Evasion

The SEC’s January 2026 order revealed that the control environment at ADM was susceptible to management override, a serious vulnerability where senior executives can bypass established.

The investigation found that the internal controls failed in three specific ways:

The “Remediation” Stumble of November 2024

ADM’s initial attempts to fix these controls proved insufficient, demonstrating the depth of the accounting rot. In March 2024, the company announced a remediation plan involving new for intersegment transactions. yet, while testing these very controls in the third quarter of 2024, ADM discovered additional accounting errors. On November 5, 2024, ADM was forced to cancel its earnings call and announce further restatements. The company admitted that the new testing procedures had uncovered more improper sales adjustments between the Ag Services/Oilseeds, Carbohydrate Solutions, and Nutrition segments. This relapse forced the company to amend its 2023 Form 10-K and its quarterly reports for the and second quarters of 2024. The recurrence of errors months after the initial scandal broke underscored that the control deficiencies were not incidents were deeply in the company’s financial infrastructure.

Tone at the Top

The internal control failures were exacerbated by a “tone at the top” that prioritized aggressive growth over compliance. The SEC findings indicated that the pressure to meet the “20% operating profit growth” target for the Nutrition segment created an environment where controls were viewed as obstacles rather than safeguards. When the Nutrition segment fell short of its forecasts, the absence of strong controls allowed CFO Vikram Luthar and Nutrition President Vincent Macciocchi to direct the finance department to “find” the missing profit through internal transfer adjustments. In response to these failures, ADM’s new CFO, Monish Patolawala, stated in September 2024 that addressing the “root cause” of the material weakness was a top priority. The company has since overhauled its financial leadership team and implemented stricter validation testing for all intersegment pricing, a remedial measure that the SEC as a mitigating factor in reducing the final civil penalty to $40 million.

The January 2024 Valuation Collapse

The of accounting irregularities within the Nutrition segment triggered an immediate and historic repricing of Archer-Daniels-Midland’s equity. On January 22, 2024, following the announcement that CFO Vikram Luthar had been placed on administrative leave and that the company would delay its earnings release, ADM shares experienced their single largest percentage decline since 1929. The stock plummeted approximately 24% in a single trading session, closing at $51. 49, down from the previous close of roughly $68. 19. This violent correction erased $8. 8 billion in market capitalization in roughly six hours of trading. The sell-off was not a reaction to a missed earnings target a fundamental rejection of the company’s valuation multiple. For years, ADM executives had pitched the Nutrition segment as a high-margin, high-growth differentiator that justified a premium over traditional commodity traders like Bunge or Cargill. Investors had priced ADM stock based on the belief that the Nutrition unit would deliver the promised 15-20% annual operating profit growth. When the internal probe revealed that these margins were artificially supported by intersegment transfer pricing, the “Nutrition premium” evaporated instantly. The market re-rated ADM from a diversified food ingredient innovator back to a standard grain handler, a business model that historically commands significantly lower price-to-earnings (P/E) ratios.

Table 1: The Crash Mechanics (January 22, 2024)

Analyst Downgrades and Institutional Exodus

The response from Wall Street was swift and punitive. In the 48 hours following the disclosure, at least four major brokerages downgraded the stock, citing a complete loss of visibility into the company’s true earnings power. Goldman Sachs downgraded ADM from “Buy” to “Neutral,” slashing its price target and noting that the accounting problem created an “overhang” that would until the SEC and DOJ investigations concluded. Baird and Roth MKM followed suit, removing their “Outperform” ratings. The core concern for analysts was not just the dollar amount of the misstatement, which ADM later quantified as a relatively contained impact on consolidated earnings, the destruction of the “growth narrative.” Institutional investors, including pension funds and ESG-focused portfolios, reduced exposure to ADM due to the governance red flags. The uncertainty regarding the 10-K filing, which was delayed until March 2024, further exacerbated volatility. During this “dead money” phase in Q1 and Q2 2024, ADM stock languished in the low $50s, unable to participate in the broader market rallies that lifted the S&P 500.

The Bunge: Opportunity Cost

The true cost of the scandal for ADM shareholders is best illustrated by comparing its performance to its primary publicly traded rival, Bunge Global SA (BG). While ADM spent 2024 and 2025 mired in forensic audits, restatements, and executive shuffles, Bunge capitalized on favorable crush margins and the Viterra acquisition integration. By late 2025, a clear emerged. Morgan Stanley, in a December 2025 research note, upgraded Bunge to “Overweight” while simultaneously downgrading ADM to “Underweight.” The analysts “idiosyncratic risk” at ADM, a polite euphemism for the self-inflicted wounds of the accounting fraud, as the primary reason for the valuation gap. While Bunge traded at a premium due to its clean execution and realization, ADM traded at a discount, load by the lingering DOJ investigation and the skepticism surrounding its Nutrition unit’s profitability.

Table 2: Comparative Performance (Jan 2024 , Jan 2026)

“The investment debate has shifted from broad macro forces to company-specific execution. We view Bunge’s bull-to-bear skew as significantly more attractive than ADM’s, given the lingering idiosyncratic risks.” , Morgan Stanley Research Note, December 16, 2025

Recovery Lag and the “Show Me” Story

Throughout 2025, ADM stock entered a slow, grinding recovery phase. The share price bottomed out near $41 in April 2025, a 52-week low that reflected maximum pessimism. From that trough, the stock began to climb as the company issued restated financials that, while embarrassing, confirmed that the cash flows remained largely intact. The market began to treat ADM as a deep value play, the “growth” investors had departed. The recovery was by the “show me”. Every quarterly earnings call in 2025 was dominated by questions regarding the Nutrition segment’s *real* margins. Without the artificial boost from the “retroactive rebates” and intersegment transfers, Nutrition operating profits fell by over 30% year-over-year. This reality check kept a ceiling on the stock price. Investors refused to pay a premium multiple for a business unit that was performing no better than the volatile commodities trading division.

January 2026: The Settlement Relief Rally

On January 27, 2026, when the DOJ formally declined to prosecute and the SEC finalized the $40 million civil penalty, ADM stock reacted with a muted “relief rally.” Shares rose approximately 1. 3% to close at $68. 23. While this price point marked a return to the pre-crash levels of January 2024, it represented two lost years of capital appreciation for shareholders. The market’s reaction signaled that the worst-case scenario—criminal indictments against the corporation or a forced divestiture of the Nutrition unit—had been avoided. Yet, the valuation damage. As of February 2026, ADM trades at a forward P/E of approximately 14x, a discount to its historical average of 16x and a discount to peers with cleaner governance records. The $8. 8 billion wiped out in January 2024 has technically been recovered in nominal terms, when adjusted for inflation and the opportunity cost of missing the broader market’s 40% rally over the same period, long-term shareholders remain significantly underwater. The “Nutrition” narrative, once the driver of a $50 billion valuation target, is viewed as a liability. The market values ADM almost exclusively on its Ag Services and Carbohydrate Solutions—the legacy grain and ethanol businesses— assigning zero or negative value to the “strategic growth” pledge of the past decade.

Operational: 2025 Workforce Reductions and Cost Cutting

In direct response to the financial caused by ongoing accounting investigations and market volatility, Archer Daniels Midland (ADM) initiated a sweeping operational restructuring in early 2025. The company confirmed the elimination of 600 to 700 roles globally as part of a broader strategy to stabilize its balance sheet following a $12 billion in market value linked to the Nutrition segment accounting scandal.

During the Q4 2024 earnings call on February 4, 2025, CEO Juan Luciano announced a multi-year cost-reduction program targeting $500 million to $750 million in total savings. For the fiscal year 2025 alone, ADM set an immediate target to strip $200 million to $300 million from its operating expenses. These measures were framed as necessary to address “softer market conditions” and “policy uncertainty,” though they coincided directly with the company’s efforts to remediate material weaknesses in its financial reporting.

Targeted Reductions and Strategic Exits

The workforce reductions were not evenly distributed. Reports from April 2025 indicated that ADM’s global commodity trading desk in Rolle, Switzerland, faced specific cuts, with at least eight senior traders and managers let go. This move signaled a retreat from certain high-risk trading positions as the company prioritized liquidity and core operational efficiency.

Management also executed a “portfolio simplification” strategy, identifying approximately $2 billion in assets for chance divestiture or closure. This included shutting down underperforming lines within the Animal Nutrition subsegment, which had been the epicenter of the accounting irregularities. The company reported that the Nutrition segment’s operating profit had previously collapsed, necessitating a complete overhaul of its cost structure to restore investor confidence.

Executive Compensation and Accountability

The operational extended to the C-suite. In a move reflecting the severity of the emergency, the ADM board slashed CEO Juan Luciano’s 2024 cash bonus to $1. 2 million, less than half of his $3 million target. This reduction brought his total compensation down to approximately $21. 6 million, a decrease from $24. 4 million the prior year. Simultaneously, former CFO Vikram Luthar faced civil charges from the SEC for allegedly directing the “adjustments” that inflated Nutrition segment operating profit, further cementing the link between the accounting probe and the company’s austere 2025 fiscal policies.

Financial Impact of 2025 Restructuring

The restructuring efforts faced immediate headwinds. While the Nutrition segment showed signs of stabilization in early 2025, the Ag Services & Oilseeds (AS&O) segment reported a 31% decline in operating profit in Q4 2024, driven by lower crush margins and export activity. This compounded the urgency for the announced cuts, as the company could no longer rely on record trading profits to mask the structural exposed by the investigation.

Consolidated Class Action: The Battle for Billions

While Archer-Daniels-Midland (ADM) secured a definitive end to federal investigations in January 2026 through a $40 million civil penalty and a Department of Justice declination, the company faces a far more expensive legal threat in the Northern District of Illinois. As of February 2026, the consolidated shareholder class action, Chow v. Archer-Daniels-Midland Company et al., has moved into the discovery phase, following a pivotal judicial ruling that stripped the defense of its early exit strategy. Unlike the SEC settlement, which capped liability at a fraction of the company’s annual revenue, the civil litigation seeks damages commensurate with the $8. 8 billion market capitalization loss suffered by investors during the stock’s collapse in January 2024.

Procedural Posture: The Motion to Dismiss Failure

The trajectory of the litigation shifted decisively on March 12, 2025, when U. S. District Judge Thomas M. Durkin denied ADM’s motions to dismiss in their entirety. In securities litigation, the motion to dismiss is the primary filter; surviving it forces defendants to choose between a massive settlement or intrusive discovery. Judge Durkin’s opinion dismantled ADM’s defense that the accounting errors were mere negligence.

The court found that the plaintiffs, led by the National Elevator Industry Pension Fund and KBC Asset Management NV, had sufficiently pleaded “scienter,” or intent to defraud. The ruling specifically highlighted the timing of executive compensation changes. Judge Durkin noted that two years after the improper accounting practices began, ADM’s board altered the compensation structure to tie executive bonuses directly to the Nutrition segment’s operating profit. This modification, the court reasoned, created a plausible motive for executives to maintain the accounting irregularities, as their personal financial outcomes were tethered to the specific metric being manipulated.

Lead Plaintiffs and Counsel

The litigation is spearheaded by institutional heavyweights rather than individual retail investors, signaling the high of the claim. The court appointed the National Elevator Industry Pension Fund and KBC Asset Management NV as Lead Plaintiffs, represented by Robbins Geller Rudman & Dowd LLP. This firm, known for securing the $7. 2 billion Enron settlement, has aggressively targeted the between ADM’s public statements about the Nutrition segment’s “explosive growth” and the internal reality of stalled demand and transfer pricing manipulation.

“Defendants’ compensation was directly tied to the profits of the Nutrition segment specifically, rather than that of ADM as a whole. This chain of events plausibly suggests a motive to at least maintain the fraudulent practice.”
, U. S. District Judge Thomas M. Durkin, Memorandum Opinion and Order, March 12, 2025

The: SEC Settlement vs. Civil Liability

A serious friction point has emerged between the regulatory resolution and the civil lawsuit. On January 28, 2026, ADM settled with the SEC without admitting or denying the findings. yet, the factual admissions required by the settlement, specifically regarding the material inflation of the Nutrition segment’s operating profit, provide ammunition for the class action plaintiffs.

even with the regulatory truce, ADM spokesperson Jackie Anderson stated in late January 2026 that the company would “vigorously defend” against the shareholder lawsuits. This bifurcated strategy is common risky: ADM paid $40 million to silence the regulator must to a federal jury that the same conduct, which the SEC deemed a violation of antifraud provisions, did not intentionally deceive shareholders. The “no admission” clause in the SEC deal prevents the plaintiffs from using the settlement as automatic proof of guilt, the underlying documents and the SEC’s detailed complaint likely serve as a roadmap for the plaintiffs’ discovery requests.

Damages and the Class Period

The certified class period currently spans from April 30, 2020, to January 22, 2024. This timeframe captures the era when ADM aggressively touted the Nutrition segment as a high-growth diversifier to offset the volatility of its traditional grain trading business. The plaintiffs allege that the artificial inflation of Nutrition profits caused the stock to trade at unjustifiable premiums. When the accounting probe was revealed, the stock plunged 24% in a single day, the largest drop since 1929.

The Luthar Factor

The refusal of former CFO Vikram Luthar to settle with the SEC adds a volatile variable to the class action. Because Luthar is fighting the SEC charges in court, his defense may force the disclosure of internal communications and board minutes that ADM would prefer to keep sealed. If Luthar testifies that other executives or board members were aware of the transfer pricing adjustments, a defense strategy to prove he was not a “rogue actor”, that testimony would be directly admissible in the shareholder case. The class action plaintiffs are likely to depose Luthar early in the discovery process, using his regulatory battle to pry open the corporate suite’s internal deliberations.

The End of “Retroactive” Adjustments

The regulatory settlements finalized in January 2026 were predicated not on financial penalties, on a detailed structural overhaul of Archer-Daniels-Midland’s (ADM) internal accounting architecture. At the center of this remediation was the of the unclear intersegment transfer pricing method that allowed executives to shift profit arbitrarily between divisions. Under the terms of the DOJ’s declination and the SEC’s cease-and-desist order, ADM was required to implement rigorous new ensuring all intersegment sales, specifically those between the Ag Services and Oilseeds segments and the Nutrition segment, are recorded at strictly verified market rates.

The remediation explicitly prohibits the use of “retroactive rebates,” the primary lever used by former CFO Vikram Luthar to manufacture profitability. Previously, executives could look back at a quarter’s performance, identify a shortfall in the Nutrition segment, and retroactively lower the price of ingredients (such as soy protein or ethanol) that Nutrition had “purchased” from other ADM divisions. This practice, which the SEC described as “one-sided transfers of operating profit,” has been replaced by a real-time, market-based pricing model. Transfer prices must be set largely in advance based on third-party benchmark data, eliminating the retrospective discretion that facilitated the fraud.

Material Weakness and Control Architecture

The overhaul was necessitated by the identification of a “material weakness” in ADM’s internal control over financial reporting (ICFR), disclosed in March 2024 and reiterated in the company’s restated 2023 Form 10-K filed in November 2024. The weakness was specifically located in the company’s inability to validate that intersegment sales were occurring at arm’s-length prices. To cure this, ADM engaged outside forensic accounting experts to reconstruct the pricing history of thousands of transactions and establish a new control framework.

Key Remediation Measures Implemented (2024, 2026)

During the February 4, 2026, earnings call, CEO Juan Luciano acknowledged that while the new controls were “designed and implemented,” the company was still in the process of “testing the operating effectiveness” of these measures to ensure sustainability. This testing period is a serious final step before the material weakness can be formally classified as “remediated” in the company’s 2025 Annual Report.

Personnel and Governance Restructuring

The remediation extended beyond spreadsheets to the executive hierarchy. The departure of Vikram Luthar was followed by the appointment of Monish Patolawala as CFO and, crucially, the hiring of Carrie Nichol as Chief Accounting Officer (CAO). Nichol, recruited from Cargill, was tasked with professionalizing the controller function and severing the cozy relationships that had allowed business unit leaders to pressure finance staff into making “top-side” adjustments.

Under the new governance structure, the finance function for the Nutrition segment no longer reports solely to the Nutrition President has a solidified “dotted line” reporting relationship to the corporate controller. This structural change is designed to prevent the “siloing” that allowed Vincent Macciocchi to run the Nutrition segment as a personal fiefdom where accounting rules were treated as suggestions rather than mandates.

“The adjustments related to the Company’s reporting segments do not impact our consolidated statement of earnings… [yet] we have developed a remediation plan with respect to the identified material weakness to enhance the reliability of our financial statements.”
, Juan Luciano, ADM CEO (March 12, 2024)

Restatements and Transparency

The culmination of these efforts was the massive restatement exercise completed in November 2024. ADM restated its financial results for fiscal year 2023 and the two quarters of 2024. While the consolidated earnings remained unchanged, because the fraud involved moving money from one corporate pocket to another, the segment-level data was radically revised. The restatements revealed that the Nutrition segment’s operating profit had been artificially inflated by as much as 15-20% in certain periods, confirming that the division’s “growth story” was largely an accounting fiction.

The DOJ’s decision to decline prosecution in January 2026 was heavily influenced by these remedial steps. In its declination letter, the Justice Department ADM’s “timely and voluntary self-disclosure” and the “exceptional” nature of its remediation, which included not just firing the architects of the scheme fundamentally re-engineering the company’s financial nervous system to prioritize accuracy over narrative.

The $40 Million Infusion: Regulatory Restitution

On January 27, 2026, the Securities and Exchange Commission (SEC) formally established a Fair Fund to distribute $40 million in civil penalties paid by Archer-Daniels-Midland (ADM) directly to harmed investors. This method, triggered by the resolution of the agency’s two-year investigation into the Nutrition segment’s accounting irregularities, ensures that the financial sanctions levied against the agribusiness giant serve a restorative rather than purely punitive function. Unlike traditional fines that remit to the U. S. Treasury, the Fair Fund provision, authorized under Section 308(a) of the Sarbanes-Oxley Act of 2002, redirects these assets to the shareholders who suffered realized losses during the fraud period.

The $40 million principal is composed entirely of the civil penalty agreed to by ADM in its settlement. yet, the fund’s total capitalization exceed this baseline. The SEC’s order mandates that the disgorgement and penalties paid by former executives Vincent Macciocchi and Ray G. Young also be added to the distribution pool. Macciocchi, the former President of the Nutrition segment, agreed to pay $404, 343 in disgorgement and prejudgment interest, plus a $125, 000 civil penalty. Young, the former CFO, contributed $575, 610 in disgorgement and interest, alongside a $75, 000 penalty. These executive clawbacks bring the initial fund total to approximately $41. 18 million, exclusive of any interest that may accrue before distribution.

The Mechanics of Section 308(a)

The establishment of this Fair Fund represents a serious pivot in the enforcement action. Prior to the Sarbanes-Oxley Act, civil penalties collected by the SEC could not be distributed to victims; they were strictly government revenue. Section 308(a) fundamentally altered this, allowing the Commission to combine civil penalties with disgorgement orders into a single fund for investor relief. In the ADM case, the “Fair Fund” designation acknowledges that the accounting manipulations, specifically the inflation of Nutrition segment operating profit by up to 10% annually, distorted the company’s valuation, leading investors to purchase shares at artificially inflated prices between 2020 and 2023.

The SEC’s order explicitly cites the “significant remedial measures” undertaken by ADM as a factor in the penalty size, yet the $40 million figure remains a substantial sum for a disclosure violation. It reflects the agency’s assessment of the “net harm” inflicted on the market. When ADM’s stock plummeted 24% on January 22, 2024, erasing billions in market capitalization in a single trading session, the causal link between the accounting irregularities and investor losses was solidified. The Fair Fund is designed to address this specific delta: the difference between the price investors paid for ADM stock based on fraudulent financial reporting and the true value of the shares once the irregularities were exposed.

Defining the “Harmed Investor”

Access to the Fair Fund is not universal for all ADM shareholders. The distribution plan, which be drafted by a court-appointed Fund Administrator, strictly define the “Class Period.” Based on the timeline of the accounting violations detailed in the SEC complaint, eligibility likely be restricted to investors who purchased ADM common stock between January 2020 and January 2024 and held those shares through the corrective disclosure on January 21, 2024.

The calculation of “Recognized Loss” be the primary metric for distribution. This formula subtracts the sale price (or the holding value after the fraud was revealed) from the purchase price, adjusted for the “inflation ribbon”, the specific amount of artificial value attributed to the fraud at the time of purchase. For ADM investors, the inflation ribbon is directly tied to the Nutrition segment’s overstated operating profit. Because the Nutrition unit was marketed as a high-growth engine commanding a higher valuation multiple than the legacy grain-trading business, the “inflation” per share may be calculated not just on earnings per share (EPS) impact, on the compression of the price-to-earnings (P/E) multiple that occurred when the growth narrative collapsed.

The Administration Process: A Multi-Year Timeline

While the $40 million has been secured, the route to an investor’s bank account is bureaucratic and lengthy. The SEC must file a motion to appoint a Fund Administrator, a specialized firm like Epiq, Gilardi & Co., or Kroll, to manage the claims process. This appointment occurs within 60 to 90 days of the settlement. Once appointed, the administrator is tasked with developing a “Plan of Distribution.”

This plan is subject to public comment and Commission approval. It outline the specific methodology for calculating losses, the de minimis threshold (the minimum claim amount, frequently $10, which checks are not issued), and the tax treatment of the distribution. For ADM investors, the complexity lies in the “intersegment” nature of the fraud. Because the fraud involved shifting profits between divisions rather than fabricating revenue out of thin air, the administrator’s forensic accountants must determine exactly how much the stock price was inflated by the misclassification of profits, rather than the non-existence of profits.

The Claims Phase: Once the plan is approved, the administrator identify chance claimants using transfer agent records and data from the Depository Trust Company (DTC). Notices be mailed to beneficial owners, and a claims website be launched. Investors likely have a 90-to-120-day window to submit proof of purchase and sale.

The Review and Payout: After the claims deadline, the administrator processes the submissions, rejecting deficient claims and calculating the pro-rata share for eligible investors. If the total recognized loss of all valid claims exceeds the $41. 18 million fund (which is a near certainty given ADM’s market cap), the payout be a percentage of the recognized loss. For example, if total valid claims amount to $400 million, investors might receive roughly 10 cents on the dollar. The entire process, from the January 2026 settlement to the mailing of the distribution checks, spans 18 to 36 months.

Distinction from Private Litigation

It is imperative to distinguish the SEC Fair Fund from the parallel class-action lawsuits filed by private plaintiffs (such as the consolidated action led by Robbins Geller Rudman & Dowd LLP). The Fair Fund is a regulatory remedy, not a civil settlement. Participation in the Fair Fund does not automatically preclude an investor from participating in the private class action, although the “double recovery” rule prevents an investor from recovering more than their total actual loss.

In securities fraud cases, the Fair Fund and the class action settlement are administered separately, though they frequently use the same claims data to reduce administrative friction. The Fair Fund has distinct advantages: it does not require investors to pay attorney fees (which can consume 25-30% of a class action settlement), as the SEC’s counsel are government employees. Consequently, 100% of the $41. 18 million (minus administrative costs) goes to the victims. In contrast, private class actions frequently result in larger headline numbers lower net recovery ratios due to legal fees.

SEC Enforcement Director Margaret A. Ryan: “Transparent and honest disclosure are key to maintaining market integrity, so when ADM misled its investors, the SEC stepped in to protect them and the market. The order creates a Fair Fund to distribute the ordered monetary relief to investors harmed by the violations.”

Tax and Residual Funds

The distribution from a Fair Fund is generally treated as a return of capital for tax purposes, reducing the investor’s cost basis in the security. It is not taxed as income unless the recovery exceeds the investor’s original basis. The Fund Administrator problem tax forms (such as 1099-MISC) to recipients of significant payments.

In the event that funds remain after the initial distribution, frequently due to uncashed checks or the inability to locate certain claimants, the SEC authorizes a “residual” distribution if it is cost-. If the remaining amount is too small to justify a second round of checks, the residual funds are remitted to the U. S. Treasury. Given the high institutional ownership of ADM stock, the “cash rate” for the initial distribution is expected to be high, leaving minimal residual funds.

The creation of this fund marks the financial conclusion of the government’s case against ADM, for the investors who watched their portfolios shrink in January 2024, the restitution process is just beginning. The $40 million penalty, while significant, represents a fraction of the market value lost, serving as a symbolic and partial restorative measure rather than a complete indemnification of shareholder losses.

The Governance Premium: Credit Rating Agencies React

The of accounting irregularities in Archer-Daniels-Midland’s Nutrition segment did not equity value; it triggered an immediate and prolonged emergency of confidence among the relentless arbiters of corporate solvency: the credit rating agencies. For a company that relies heavily on short-term commercial paper to finance its massive grain trading operations, the loss of the “Stable” outlook was not an abstract reputational bruise a tangible threat to liquidity.

S&P Global: The Immediate Watchlist

On January 23, 2024, within 48 hours of CFO Vikram Luthar’s administrative leave, S&P Global Ratings placed ADM on CreditWatch with negative . This designation is the credit market’s equivalent of a defcon warning, signaling that a downgrade could be imminent pending further disclosure. S&P explicitly the “material weakness” in internal controls and the uncertainty surrounding the scope of the investigation.

By March 21, 2024, following ADM’s delayed filing of its 2023 Form 10-K, S&P removed the company from CreditWatch cemented a Negative Outlook. While the agency affirmed the ‘A’ issuer credit rating, it issued a scathing assessment of the company’s governance structure. Under S&P’s revised “Management and Governance” (M&G) criteria, published in January 2024, ADM’s risk management, internal controls, and audit practices were viewed negatively. The agency noted that while the financial restatement itself was immaterial to the balance sheet, the failure of control was material to the credit profile.

The November 2024 Relapse: Moody’s Downgrades Outlook

While ADM executives attempted to frame the scandal as a contained event resolved by the March 2024 filing, the credit agencies remained skeptical. That skepticism was validated in November 2024, when ADM was forced to restate its financials again, this time correcting the 2023 Form 10-K and the two quarters of 2024. This “second wave” of errors proved that the initial remediation efforts had failed to plug the holes in the Nutrition segment’s reporting.

On November 8, 2024, Moody’s Investors Service responded by revising ADM’s outlook to Negative from Stable, while affirming its ‘A2’ long-term rating. Moody’s rationale was blunt: the recurring accounting problem exposed persistent weaknesses in the crop trader’s control environment. The agency warned that the “distraction of management” and the open DOJ investigation presented ongoing downside risks that precluded a return to a Stable outlook.

Bond Market Realities: The Cost of Uncertainty

The rating agencies’ hesitation translated directly into the fixed-income markets. Throughout 2024 and 2025, ADM’s bond spreads, the premium investors demand to hold ADM debt over risk-free Treasuries, widened relative to its peer group (Bunge, Cargill). Investors priced in a “governance premium,” charging ADM for the risk that the DOJ investigation could escalate into criminal charges or massive fines.

The “A” rating category implies a low risk of default and strong capacity to meet financial commitments. yet, the persistent “Negative” outlooks meant that ADM traded like a “BBB” credit for much of the investigation period. Institutional investors with strict mandates regarding governance scores were forced to reduce exposure, reducing the liquidity of ADM’s bonds in the secondary market.

January 2026: The Stabilization

The resolution of the DOJ and SEC investigations in January 2026 provided the catalyst for credit stabilization. The Department of Justice’s decision to decline prosecution removed the “tail risk” of a corporate criminal conviction, which could have triggered default covenants in varying credit agreements. also, the $40 million civil penalty imposed by the SEC was financially immaterial for a company generating over $90 billion in revenue.

Following the January 27, 2026 announcement, credit analysts viewed the closure as a “credit positive” event. With the regulatory cloud lifted and the “material weakness” in internal controls reportedly remediated through the installation of new financial leadership, the route cleared for S&P and Moody’s to eventually return ADM to a “Stable” outlook, restoring its standing as a pristine investment-grade borrower.

“The affirmation of the ‘A’ rating reflects our view that ADM’s competitive position remains intact even with the governance failures. yet, the Negative outlook until the company demonstrates a sustained period of error-free reporting.” , S&P Global Ratings Rationale (March 2024)

The Valuation Gap: Manufacturing a Premium Over Bunge

For nearly a decade, Archer-Daniels-Midland (ADM) executives pitched a singular narrative to Wall Street: ADM was no longer just a commodity grain trader like its primary rival, Bunge Global SA. While Bunge remained tethered to the cyclical volatility of soy crushing and grain merchandising, ADM claimed to have evolved into a “nutrition” company, deserving of the higher valuation multiples afforded to ingredients manufacturers like Kerry Group or DSM. This strategic differentiation was the of ADM’s stock price premium. By 2024, prior to the full unraveling of the accounting scandal, ADM frequently traded at a forward price-to-earnings (P/E) ratio of approximately 14x, while Bunge languished near 8x-10x. The justification for this 40-60% valuation premium was the Nutrition segment, which ostensibly offered high margins and stable, non-cyclical growth. The Department of Justice (DOJ) and Securities and Exchange Commission (SEC) investigations revealed this premium was manufactured. By shifting profits from its Ag Services and Oilseeds division, the business most similar to Bunge, into the Nutrition segment, ADM artificially smoothed its earnings quality. The “Nutrition” profit was not organic high-margin growth; it was simply commodity trading profit dressed up as specialty ingredient revenue.

Operating Margin Analysis: The “Nutrition”

A direct comparison of operating margins between ADM and Bunge from 2020 to 2025 exposes the mechanics of the. Bunge’s margins reflected the honest, if volatile, reality of the global agribusiness sector. ADM’s reported margins, specifically within Nutrition, were smoothed to present a trajectory of linear growth that market conditions. Between 2020 and 2022, Bunge’s operating margins fluctuated significantly, driven by the Russian invasion of Ukraine and global supply chain dislocations. In contrast, ADM’s Nutrition segment reported a steady climb toward a 20% operating profit growth target.

Table 1: Comparative financial metrics showing the impact of restatements on ADM’s competitive positioning against Bunge. Note that while ADM’s consolidated margin remained unchanged, the internal allocation shifted drastically.

The “Intersegment” Shell Game

The crux of the comparison lies in the “Ag Services” divisions of both companies. Bunge’s primary revenue engine is its Agribusiness segment, which handles oilseed processing and grain origination. ADM’s equivalent is “Ag Services and Oilseeds.” During the fraud period (2018-2023), ADM’s Ag Services unit performed exceptionally well due to favorable crush margins. yet, instead of letting those profits sit in the cyclical Ag Services bucket, where investors (like Bunge’s) would discount them as temporary, ADM executives transferred them to Nutrition via “retroactive rebates.” For example, in 2022, ADM shifted approximately $68 million of profit from Ag Services/Carbohydrates into Nutrition. If ADM had reported these profits correctly, its Ag Services division would have shown even stronger results, likely mirroring or exceeding Bunge’s record 2022 performance, its Nutrition segment would have shown single-digit growth (6%) rather than the “double-digit” growth (20%) promised to Wall Street. This manipulation denied Bunge a fair comparison. Bunge was competing against an ADM that was subsidizing its specialty business with commodity profits, creating an illusion of diversification that Bunge did not claim to have.

Strategic: Viterra vs. Nutrition

While ADM was internally managing metrics to support its Nutrition narrative, Bunge pursued a different strategy: consolidation. In 2023, Bunge announced its merger with Viterra, a massive deal designed to create a global agribusiness giant capable of competing with Cargill and COFCO. Bunge’s strategy was transparently “commodity-.” They doubled down on and logistics, accepting the lower valuation multiples associated with that sector. ADM, conversely, attempted to escape the commodity label entirely. The of the 2025 investigation validated Bunge’s method. By early 2026, Bunge’s stock had significantly outperformed ADM’s. Investors rewarded Bunge for executing a clear, honest strategy, while punishing ADM for a failed pivot built on accounting irregularities. As of February 2026, Bunge’s operating margin stood at 3. 83% (TTM), reflecting a normalization of commodity markets, while ADM’s Nutrition segment struggled to regain credibility, posting a $10 million loss in Q4 2023 before a modest recovery to $130 million in Q3 2025.

“The market was rewarding them [ADM]… ADM’s board in 2020 took a rare step: It linked half of senior executives’ long-term incentive pay to Nutrition’s performance.” , Morningstar Analyst Seth Goldstein, referencing the incentives that drove the from Bunge.

2026 Market Realignment

Following the SEC settlement in January 2026, the valuation gap has inverted. Analysts at Morgan Stanley downgraded ADM to “Underweight” and upgraded Bunge to “Overweight” in December 2025. The rationale was explicit: Bunge offered ” optionality” from the Viterra deal, while ADM presented “idiosyncratic risk” and a broken growth narrative. The “Nutrition Premium” has evaporated. ADM is being valued more like Bunge—as a grain handler and processor. The irony of the scandal is that ADM’s core Ag Services business remains a powerhouse, frequently outperforming Bunge’s legacy assets in efficiency and volume. yet, by looting the Ag Services piggy bank to prop up Nutrition, ADM’s leadership obscured the strength of their core business, damaging shareholder value in a way that Bunge’s straightforward commodity focus did not. As of February 2026, ADM trades at approximately 11x forward earnings—nearly identical to Bunge’s expanded multiple—signaling that the market no longer views ADM as a “Nutrition” company, rather as a peer grain trader with a history of internal control failures.

The Watchdogs That Didn’t Bark: A widespread Failure of Oversight

The accounting scandal that engulfed Archer-Daniels-Midland (ADM) in 2024 and culminated in the January 2026 settlement was not a failure of executive management; it was a collapse of the corporate governance firewall designed to prevent such malfeasance. The Audit Committee of the Board of Directors, tasked with overseeing the integrity of financial statements and internal controls, presided over a period where the Nutrition segment’s operating profits were artificially inflated by up to 10% through crude intersegment transfer pricing manipulations. even with the presence of a “material weakness” in internal controls, a deficiency so severe it implies a reasonable possibility that a material misstatement not be prevented or detected, the Board remained passive until the Department of Justice (DOJ) issued a grand jury subpoena in January 2024. This reactive stance contradicts the Audit Committee’s primary charter: to serve as the independent guardian of shareholder interests against management overreach.

Composition and Charter Responsibilities

During the serious period of the alleged fraud (2021, 2023), the Audit Committee was comprised of independent directors who possessed significant financial and operational experience. According to the 2023 Proxy Statement, the committee was chaired by Terrell K. Crews, a former CFO of Monsanto, and included members such as Michael S. Burke and Patrick J. Moore. Their charter explicitly mandated them to “oversee the accounting and financial reporting processes” and “review the adequacy and effectiveness of the Company’s internal controls.” The specific method of the fraud, manipulating the transfer prices of goods sold from the Ag Services and Oilseeds segments to the Nutrition segment, exploited a blind spot in the committee’s oversight. While the committee met nine times in 2022, there is no public record of them challenging the anomalous profitability of the Nutrition segment, which reported “double-digit” growth while competitors and the broader market faced headwinds.

The “Material Weakness” in Internal Controls

The smoking gun of the Audit Committee’s negligence is the admission of a “material weakness” in internal control over financial reporting (ICFR). In March 2024, ADM was forced to disclose that it absence controls to validate that intersegment sales were recorded at amounts approximating market value. This was not a complex derivative failure or a cyber-breach; it was a fundamental breakdown in basic accounting hygiene. The committee failed to ensure that: 1. **Validation Existed:** There were no automated checks to flag when internal transfer prices deviated significantly from third-party market rates. 2. **Manual Entry Scrutiny:** The fraud relied on “manual adjustments” and “retroactive rebates” directed by CFO Vikram Luthar. A functioning Audit Committee reviews significant manual journal entries, especially those made near quarter-end that materially affect segment reporting. 3. **Whistleblower Channels:** The investigation was triggered by external regulatory pressure, not internal whistleblower reports, suggesting that the committee’s method for receiving anonymous employee complaints were either ineffective or ignored.

The Auditor Relationship: A Failure to Question

The Audit Committee is directly responsible for the appointment, compensation, and oversight of the external auditor, Ernst & Young (EY). The fact that EY signed off on the financial statements for 2021 and 2022 without identifying the material weakness raises serious questions about the depth of the committee’s dialogue with the auditors. In the 2023 Annual Report, the committee stated it had “reviewed and discussed” the audited financial statements with management and EY. yet, the SEC’s January 2026 order revealed that the “adjustments” were frequently made retroactively to hit specific earnings. This pattern, adjusting numbers *after* the books should have been closed, is a classic red flag. The committee failed to press EY on: * Why the Nutrition segment required significant post-period adjustments. * Whether EY had tested the “market approximation” of intersegment transfer prices. * Why the internal audit function, which reports to the committee, did not detect the gap in transfer pricing methodologies.

The “Rubber Stamp” of Unrealistic

A serious failure of the Board was the approval of the “15-20% operating profit growth” for the Nutrition segment without validating the operational feasibility of those numbers. By linking executive compensation (Performance Share Units) directly to these aggressive, the Compensation Committee created the motive for fraud, while the Audit Committee failed to police the means. The SEC investigation noted that the Nutrition segment was “struggling” operationally. Yet, the Board continued to tout the segment as the future growth engine of the company. This disconnect between operational reality and board-level narrative suggests a “rubber stamp” culture where management’s projections were accepted as fact without independent verification. The committee did not demand a “fairness opinion” or a third-party audit of the transfer pricing model until forced to do so by the DOJ.

Remediation: Too Little, Too Late

Following the exposure of the fraud, the Audit Committee scrambled to implement remedial measures. These included: * New Control Frameworks: Implementing rigorous controls around the pricing and reporting of intersegment sales. * Policy Amendments: Revising the “Intersegment Sales Policy” to require documentation and market validation for all internal transfers. * Personnel Changes: The departure of CFO Vikram Luthar and the sanctioning of Nutrition head Vincent Macciocchi. yet, these actions were taken only under the duress of a federal investigation. The “material weakness” existed for years, allowing executives to siphon value from one segment to another to mask underperformance. The $40 million civil penalty paid by ADM in January 2026 is a direct cost of this oversight failure, the reputational damage to the Board’s credibility is far greater. The Audit Committee’s inability to detect a multi-year accounting manipulation within its own walls stands as a clear example of governance negligence.

SECTION 19 of 22: Legal and Consulting Expenditures: The Cost of Defense

The Legal Phalanx: Kirkland & Ellis and Wachtell Lipton

The defense architecture erected by Archer-Daniels-Midland (ADM) to navigate the Department of Justice (DOJ) and Securities and Exchange Commission (SEC) investigations was massive, expensive, and bifurcated. To manage the dual threats of criminal liability and civil enforcement, the company deployed two of the world’s most profitable law firms. Kirkland & Ellis LLP served as primary legal counsel to the corporation, managing the broader strategic defense against the DOJ’s criminal probe and the SEC’s civil charges. Simultaneously, the Audit Committee of the Board of Directors retained Wachtell, Lipton, Rosen & Katz to conduct the independent internal investigation into the Nutrition segment’s accounting practices.

This division of labor is standard in high- corporate crises to preserve the independence of the internal probe, it significantly multiplies the burn rate of legal fees. While Kirkland & Ellis focused on shielding the corporate entity from the DOJ’s Fraud Section, Wachtell Lipton’s mandate involved an exhaustive forensic review of intersegment transactions, requiring the collection and analysis of millions of documents and interviews with dozens of executives. The costs associated with this “cooperation” were not administrative; they were the price of admission for the DOJ’s eventual declination to prosecute.

Quantifying the “Elevated” Costs

ADM did not disclose a standalone line item for “investigation expenses” in its primary financial statements, burying the specific dollar figure within its broader “Corporate and Other” segment costs. yet, a forensic review of the company’s earnings calls and segment data reveals the financial footprint of the scandal.

In the third quarter of 2024, ADM projected its full-year corporate costs to land between $1. 7 billion and $1. 8 billion. Management explicitly “elevated legal costs” as a material headwind during the Q4 2024 earnings call on February 4, 2025. These costs neutralized savings the company had achieved through other efficiency measures. By the end of 2025, the financial had intensified; during the Q4 2025 earnings call on February 3, 2026, ADM reported that corporate and other business costs had surged approximately 25% compared to the prior year.

While of this increase was attributed to revaluation losses, the sustained “elevated” nature of these expenses confirms that the defense strategy, culminating in the $40 million SEC penalty and DOJ clearance, was a nine-figure undertaking when factoring in legal fees, forensic accounting, and data preservation.

The Insurance Misconception

Investors analyzing ADM’s cash flows in 2024 and 2025 frequently noted “insurance recoveries” in the company’s financial reports, leading to a misconception that the legal defense was subsidized by carriers. This is factually incorrect. The $84 million in insurance recoveries recorded in 2024 and the projected $10 million in 2025 were related to property and business interruption claims for the Decatur East processing facility incident, not Directors and Officers (D&O) liability coverage.

Standard D&O policies frequently contain “fraud exclusions” that allow insurers to withhold advancement of legal fees if deliberate misconduct is established, or to claw them back upon a final adjudication of fraud. With the SEC charging former CFO Vikram Luthar with violating antifraud provisions, and ADM settling books-and-records charges, the load of the legal defense fell squarely on the company’s balance sheet, diluting shareholder equity without the buffer of insurance payouts for the investigation itself.

Remediation as a Recurring Cost

Beyond the hourly rates of top-tier litigators, the “cost of defense” included a massive investment in remediation to satisfy regulators. The DOJ’s decision to close its investigation without charges was predicated on ADM’s “extensive actions” to enhance internal controls. This involved not just rewriting policy manuals deploying new financial reporting infrastructure.

Throughout 2024 and 2025, ADM incurred significant costs related to the “1ADM” business transformation program, a digital overhaul intended to standardize data across segments. While originally an operational initiative, 1ADM became a serious component of the remediation effort, allowing for better visibility into the intersegment transfer pricing that had been manipulated. The acceleration of these “global technology investments” to prove compliance to the SEC added another of expense to the Corporate segment, further inflating the cost of moving past the scandal.

The Executive Offset

Ironically, the fraud itself provided a partial funding method for its own defense. In 2024, ADM slashed incentive compensation for its executive team, a direct consequence of the failure to meet the falsified performance. During the Q3 2024 earnings call, management noted that the $1. 7 billion corporate cost bucket was actually lower than it might have been, primarily due to “lower incentive compensation.” In essence, the millions of dollars that would have been paid in bonuses to the executives who oversaw the irregularities were instead repurposed to pay the lawyers hired to investigate them.

Table: Estimated Financial Impact of Defense & Remediation (2024-2025)

“We expect the benefit of cost actions… to be more than offset by the elevated legal costs.”
, ADM Management, Q4 2024 Earnings Call (Feb 4, 2025)

The Valuation Reality Check: Animal Nutrition Goodwill Impairment

The forensic unraveling of Archer-Daniels-Midland’s Nutrition segment culminated in a clear admission of lost value: a $137 million goodwill impairment charge recorded for the Animal Nutrition reporting unit in 2023. This write-down was not a bookkeeping adjustment; it was the tangible financial evidence that the segment’s actual cash flows could no longer support the inflated asset values carried on the company’s balance sheet. For years, the “growth engine” narrative had shielded these assets from scrutiny, the cessation of intersegment accounting manipulation forced ADM to confront the economic reality of its underperforming acquisitions.

The impairment was triggered by a quantitative assessment that revealed the fair value of the Animal Nutrition unit had fallen its carrying value. According to ADM’s filings, this decline was driven by “changes in the underlying business performance,” a euphemism for the unit’s inability to generate the profits promised to investors without the aid of artificial transfer pricing subsidies. The charge signaled that the premium ADM had paid for various animal nutrition assets, including the $1. 54 billion acquisition of Neovia in 2019, had partially evaporated.

Breakdown of Nutrition Segment Impairments (2023-2024)

The correction of historical financial statements necessitated a series of write-downs as the company scrubbed its books of the inflated valuations sustained by the accounting irregularities. The following table details the specific impairments and charges allocated to the Nutrition segment during the remediation period.

The Wild Flavors Legacy and Human Nutrition

While the Animal Nutrition unit bore the brunt of the immediate goodwill impairments, the Human Nutrition sub-segment, anchored by the massive $3 billion acquisition of Wild Flavors in 2014, faced its own valuation reckoning. The Wild Flavors deal was the of ADM’s pivot from commodity processing to value-added ingredients. yet, the investigation revealed that the segment’s reported stability was partly manufactured. By 2024, the Human Nutrition unit saw its operating profit plummet 22% to $327 million, a figure that exposed the unit’s standalone struggle to maintain margins once stripped of favorable intersegment transfer pricing.

The “Wild” legacy assets were meant to provide a hedge against commodity volatility. Instead, they became a source of volatility themselves. In the fourth quarter of 2023, the Human Nutrition segment posted a shocking operating loss of $25 million, down $112 million from the prior year. This collapse in profitability raised serious questions about the long-term carrying value of the Human Nutrition goodwill. While ADM avoided a massive goodwill impairment for Human Nutrition in 2024, the unit’s “fair value” cushion narrowed significantly, leaving it to future write-downs if growth remain elusive.

“Specified Items”: The Non-GAAP Shield

To manage the of these write-downs, ADM aggressively utilized “specified items”, non-GAAP adjustments that exclude certain costs from “adjusted earnings per share.” By classifying the $137 million goodwill impairment and subsequent trademark write-offs as specified items, executives removed these losses from the primary performance metric used by Wall Street analysts. This accounting maneuver allowed ADM to present a “clean” adjusted earnings figure even as the statutory GAAP earnings were dragged down by the deterioration of the Nutrition segment’s asset base.

“The auditing of the Company’s Animal Nutrition goodwill impairment charge was complex and highly judgmental… the fair value estimate was sensitive to significant assumptions such as revenue growth rates and projected EBITDA margins.” , ADM 2023 Form 10-K

This reliance on “judgmental” assumptions highlights the precarious nature of the segment’s valuation. The $228 million in operating profit that was erased from the Nutrition segment’s history (2018, 2023) due to the restatement directly undercut the cash flow models used to justify these asset values. When the artificial profits were removed, the mathematical justification for the assets’ high book value weakened, forcing the company to recognize the impairments that had been delayed by the accounting scheme.

Operational Contraction and Asset Rationalization

The valuation emergency precipitated a physical contraction of the Nutrition business. In 2024, ADM slashed two-thirds of its Nutrition brands and reduced product offerings by 17% in an effort to stabilize the segment’s margins. This “strategic simplification” was a tacit admission that the segment had become bloated with low-value assets that could not survive without the subsidy of the accounting irregularities. The company also shuttered more than 20 production lines within the Animal Nutrition sub-segment, converting what were once “growth assets” into discontinued operations and write-off candidates.

The closure of these lines and the abandonment of trademarks resulted in the $43 million impairment charge in 2024. These actions represent the tangible cost of the “growth mirage”: capital was deployed to acquire and build assets based on falsified profit projections, only to be written down and scrapped when the financial engineering was exposed. The “Nutrition” segment, once touted as a $1 billion operating profit powerhouse, ended 2024 with a restated reality of $386 million in operating profit, a fraction of the valuation implied by the billions spent on acquisitions.

The “Growth Engine” Stalls: A Decade of Decline

For over a decade, Archer-Daniels-Midland executives pitched the Nutrition segment as the company’s future, a high-margin counterweight to the cyclical volatility of commodity grain trading. This strategy hinged on the 2014 acquisition of Wild Flavors for $3 billion (€2. 3 billion), the largest deal in ADM’s history at the time. By February 2026, yet, the “growth engine” narrative had collapsed under the weight of accounting scandals and operational failures. The strategic review initiated in the wake of the DOJ and SEC investigations has forced a sober reassessment of the unit’s viability, revealing a business that is not only smaller than promised fundamentally broken in its current structure.

The between the segment’s and its actual performance is clear. In 2018, CEO Juan Luciano distributed stress balls to employees printed with “1B X 2020,” setting a goal of $1 billion in operating profit for the Nutrition unit by 2020. Six years later, the unit has never achieved that figure. Restated financials for 2025 show the Nutrition segment generated only $417 million in operating profit, less than half of the target set nearly a decade prior.

2025 Financial Autopsy: The Cost of Correction

The conclusion of the 2025 fiscal year provided the unvarnished look at the Nutrition unit’s true financial health, stripped of the internal transfer pricing manipulations that had artificially inflated its margins. The numbers released on February 3, 2026, paint a picture of a business struggling to regain its footing.

While the full-year operating profit rose slightly to $417 million, the fourth quarter of 2025 saw a renewed decline, dropping 11% year-over-year to $78 million. This drop was partly attributed to the absence of insurance proceeds that had 2024 figures, specifically related to the Decatur East facility explosion. The Human Nutrition subsegment, once the crown jewel, contracted by 2% in 2025, weighed down by weak demand for plant-based proteins and continued pricing pressure in texturants.

The Akralos Pivot: Breaking Up the Animal Nutrition Unit

The most significant outcome of the strategic review materialized on February 13, 2026, with the launch of Akralos, a joint venture with Alltech. This move signals ADM’s retreat from managing Animal Nutrition as a wholly-owned, integrated entity. By combining its North American animal feed operations with Alltech’s specialty nutrition assets, ADM aims to offload the operational volatility that plagued the unit throughout 2023 and 2024.

“Akralos ties directly into the company’s existing footprint… the joint venture brings that activity together with Alltech’s established brands. The launch… could influence how ADM competes with other large feed and nutrition providers.” , Simply Wall St, February 13, 2026

Analysts view the Akralos deal as a “soft spin-off,” allowing ADM to deconsolidate a portion of the low-margin feed business while retaining a stake in chance upside. It is a tacit admission that the integrated “farm to fork” strategy for animal nutrition failed to deliver the synergies promised to investors.

Divestiture and Downsizing: The $2 Billion Sell-Off

Beyond the Akralos joint venture, the strategic review has triggered a broader liquidation of non-core assets. In late 2025, ADM identified approximately $2 billion in divestiture opportunities to simplify the portfolio. This includes the exit from underperforming facilities in Ecuador and Brazil, as well as the closure of the Bushnell protein facility.

The human cost of this restructuring has been severe. In a cost-cutting drive announced alongside the 2024 restatements, ADM eliminated 700 positions, primarily within the Nutrition and central administrative functions. These cuts aim to generate $750 million in savings over three years, a necessary measure to prop up margins that can no longer rely on accounting gimmicks.

Market Verdict: A “Show Me” Story

The market’s reaction to the strategic review has been lukewarm. As of late February 2026, ADM stock trades near $69. 50, with most analysts maintaining a “Hold” rating. The consensus price target hovers around $60, reflecting skepticism about the Nutrition unit’s ability to return to double-digit growth.

The premium valuation once assigned to ADM stock, based on the premise that it was transforming into a high-tech ingredients company, has evaporated. The company is valued largely as a traditional agricultural commodity trader, with the Nutrition segment viewed as a “rehabilitation project” rather than a growth driver. The 2014 Wild Flavors acquisition, while still generating cash, has failed to transform the company’s fundamental economics, leaving ADM tethered to the same crop pattern and crush margins it sought to escape.

The Survivor: Luciano Retains Command Amidst Executive Purge

While the Department of Justice and Securities and Exchange Commission investigations decimated Archer-Daniels-Midland’s financial and operational leadership, one figure emerged from the wreckage largely intact: Chairman and CEO Juan Luciano. As of February 2026, Luciano retains his triple title, Chairman, President, and CEO, even with the fraud occurring under his direct oversight during the aggressive expansion of the Nutrition segment he championed.

The contrast between Luciano’s fate and that of his lieutenants is clear. Former CFO Vikram Luthar faces federal civil fraud charges and a chance officer bar. Former Nutrition President Vincent Macciocchi and former CFO Ray Young paid personal penalties and accepted sanctions. Luciano, conversely, faced no charges from federal regulators. His survival signals a calculated decision by the ADM Board of Directors to prioritize continuity over a complete leadership overhaul, even as the company paid $40 million to settle allegations of accounting fraud.

The Board did, yet, impose financial consequences on the chief executive. In March 2025, ADM’s compensation committee exercised “negative discretion” regarding Luciano’s pay. His 2024 cash bonus was slashed to approximately $1. 2 million, less than half of his $3 million target. Consequently, his total compensation for the year dropped to $21. 6 million, down from $24. 4 million in 2023. The filing explicitly stated that while no executive was found to be personally engaged in improper conduct beyond those charged, the penalty reflected accountability for the “relevant leadership positions during the applicable period.”

Governance Reforms and the “Clawback” Policy

In the wake of the scandal, ADM implemented a series of governance reforms designed to signal rigorous oversight to rattled investors. The most significant structural change was the introduction of a strengthened “clawback” policy for equity incentive awards. Under the new rules, the company can recoup stock awards if an executive engages in prohibited conduct, a power that extends even to executives who remain employed by the company, closing a previous loophole that favored retention over accountability.

Personnel changes were also used to reset the corporate narrative. The appointment of Monish Patolawala as CFO in August 2024 brought an outsider’s perspective to the C-suite. Patolawala, formerly the CFO of 3M and GE Healthcare, was tasked with remediating the material weaknesses in internal controls that allowed the Nutrition segment’s profit manipulation to go for years.

The Board of Directors also saw fresh blood with the appointment of David R. McAtee II, Senior Executive Vice President and General Counsel of AT&T, in November 2024. McAtee’s legal background was viewed as a strategic addition to the Audit and Nominating/Corporate Governance committees, reinforcing the board’s capacity to police internal compliance method.

Shareholder Dissent and Market Reaction

Luciano’s retention has not been universally accepted by the shareholder base. Following the of the accounting irregularities and the subsequent stock plunge, ADM shares lost nearly 30% of their value between January 2024 and January 2025, vocal critics emerged. Hartwig Fuchs, a former executive at an ADM-owned trading firm and a significant shareholder, publicly called for Luciano’s resignation in late 2024. Fuchs argued that the “fish stinks from the head” and that a CEO who oversaw a period of fraudulent growth could not credibly lead the recovery.

Institutional investors have remained quieter, though the stock’s performance reflects lingering skepticism. Analysts noted that while the January 2026 settlements removed the immediate regulatory overhang, the company’s valuation continues to suffer from a “governance discount.” The market’s hesitation suggests that trust in ADM’s financial reporting require more than just paid fines to restore; it demands a demonstrated period of clean audits and transparent growth.

Strategic Pivot: Portfolio Optimization

To shift the focus away from the Nutrition scandal, Luciano and the new leadership team have pivoted to a strategy of “portfolio optimization” and cost discipline. In the Q4 2025 earnings call, management outlined a plan to achieve $500 million to $750 million in cost savings over the two years. The company also provided a 2026 adjusted EPS outlook of $3. 60 to $4. 25, attempting to anchor investor expectations in future operational efficiency rather than past growth narratives.

This strategic shift implicitly acknowledges the failure of the previous era’s aggressive growth-at-all-costs method in the Nutrition segment. By focusing on margin recovery and “operational excellence,” ADM is the high-pressure environment that incentivized the accounting manipulations in the place.

Report Conclusion: The Cost of the “Growth Mirage”

The resolution of the DOJ and SEC investigations in January 2026 marks the end of a damaging chapter in Archer-Daniels-Midland’s 120-year history. What began as an ambitious corporate transformation into high-margin nutrition ingredients devolved into a case study of accounting manipulation. The “Nutrition” segment, once touted as the engine of the future, became a liability that cost the company millions in fines, the reputations of top executives, and eroded billions in shareholder value.

While the corporate entity has settled its debts to the government, the internal scars remain. The in outcomes, jail threats for, reduced bonuses for others, highlights the complex reality of corporate accountability. As ADM moves forward into 2026, it does so with tighter controls, a chastened leadership team, and a market that likely verify every number before it trusts again.